{"id":26950,"date":"2025-06-24T15:33:20","date_gmt":"2025-06-24T12:33:20","guid":{"rendered":"https:\/\/www.clinica-sante.com\/ro\/analize-fara-categorie\/hla-clasa-iigenotipare-hla-dq-si-hla-dr\/"},"modified":"2026-06-19T18:29:44","modified_gmt":"2026-06-19T15:29:44","slug":"hla-clasa-iigenotipare-hla-dq-si-hla-dr","status":"publish","type":"product","link":"https:\/\/www.clinica-sante.com\/ro\/analize-diagnostic-genetic\/hla-clasa-iigenotipare-hla-dq-si-hla-dr\/","title":{"rendered":"HLA Clasa II,genotipare HLA-DQ si HLA-DR"},"content":{"rendered":"

HLA clasa II \u2013 genotipare HLA-DR \u0219i HLA-DQ (DR4, DQ2, DQ8, DQB1*06:02)<\/h3>\n

Descriere scurt\u0103<\/h3>\n

Analiz\u0103 genetic\u0103 de tip HLA clasa II<\/strong>, care determin\u0103 alelele din regiunile HLA-DR \u0219i HLA-DQ<\/strong>, inclusiv variantele clinice relevante DR4, DQ2, DQ8 \u0219i DQB1*06:02<\/strong>. Testul este utilizat \u00een evaluarea predispozi\u021biei la boli autoimune, diabet zaharat tip 1, boal\u0103 celiac\u0103 \u0219i narcolepsie.<\/p>\n

Descriere detaliat\u0103<\/h3>\n

Sistemul HLA (Human Leukocyte Antigen)<\/strong> clasa II joac\u0103 un rol esen\u021bial \u00een prezentarea antigenelor c\u0103tre limfocitele T helper, av\u00e2nd impact major asupra regl\u0103rii r\u0103spunsului imun adaptativ.<\/p>\n

Aceast\u0103 analiz\u0103 de HLA clasa II (HLA2) investigheaz\u0103 locusurile:<\/h3>\n
    \n
  • HLA-DR<\/li>\n
  • HLA-DQ<\/li>\n<\/ul>\n

    cu raportarea alelelor clinice:<\/h3>\n
      \n
    • HLA-DR4<\/li>\n
    • HLA-DQ2<\/li>\n
    • HLA-DQ8<\/li>\n
    • HLA-DQB1*06:02<\/li>\n<\/ul>\n

      Aceste variante sunt asociate cu predispozi\u021bii imunogenetice pentru multiple afec\u021biuni autoimune \u0219i neurologice, fiind utilizate frecvent \u00een stratificarea riscului genetic.<\/p>\n

      Indica\u021bii de testare<\/h3>\n
        \n
      • Susceptibilitate la boli autoimune<\/li>\n
      • Suspiciune de diabet zaharat tip 1 (HLA-DR4, DQ2, DQ8)<\/li>\n
      • Boal\u0103 celiac\u0103 (HLA-DQ2 \/ DQ8)<\/li>\n
      • Narcolepsie (HLA-DQB1*06:02)<\/li>\n
      • Boli inflamatorii \u0219i autoimune sistemice<\/li>\n
      • Evaluare imunogenetic\u0103 familial\u0103<\/li>\n
      • Investiga\u021bii \u00een boli endocrine autoimune<\/li>\n
      • Predispozi\u021bie genetic\u0103 \u00een contexte clinice complexe<\/li>\n<\/ul>\n

        Cui se adreseaz\u0103<\/h3>\n
          \n
        • Pacien\u021bilor cu suspiciune de boli autoimune<\/li>\n
        • Pacien\u021bilor cu diabet zaharat tip 1 sau risc crescut<\/li>\n
        • Persoanelor cu simptome digestive sugestive de boal\u0103 celiac\u0103<\/li>\n
        • Pacien\u021bilor cu somnolen\u021b\u0103 excesiv\u0103 \/ suspiciune narcolepsie<\/li>\n
        • Medicilor endocrinologi, gastroenterologi, neurologi \u0219i imunologi<\/li>\n
        • Persoanelor cu istoric familial de boli autoimune<\/li>\n<\/ul>\n

          Metodologie de testare<\/h3>\n
            \n
          • Extrac\u021bie ADN din s\u00e2nge periferic (EDTA)<\/li>\n<\/ul>\n

            Genotipare HLA clasa II prin metode moleculare (PCR-SSO \/ PCR-SSP \/ secven\u021biere HLA de rezolu\u021bie variabil\u0103)<\/h3>\n
              \n
            • Identificarea alelelor HLA-DR \u0219i HLA-DQ<\/li>\n
            • Raportarea variantelor clinice relevante (DR4, DQ2, DQ8, DQB1*06:02)<\/li>\n
            • Interpretare imunogenetic\u0103 \u00een context clinic<\/li>\n<\/ul>\n

              Beneficii \u0219i importan\u021b\u0103 clinic\u0103<\/h3>\n
                \n
              • Identific\u0103 predispozi\u021bia genetic\u0103 la boli autoimune<\/li>\n
              • Sprijin\u0103 diagnosticul bolii celiace \u0219i al diabetului tip 1<\/li>\n
              • Ajut\u0103 la evaluarea riscului de narcolepsie<\/li>\n
              • Permite stratificarea riscului imunologic familial<\/li>\n
              • Contribuie la medicina personalizat\u0103 \u00een imunologie \u0219i endocrinologie<\/li>\n
              • Ofer\u0103 informa\u021bii utile \u00een evaluarea bolilor inflamatorii cronice<\/li>\n
              • Sprijin\u0103 deciziile de screening \u0219i monitorizare precoce<\/li>\n<\/ul>\n

                Analize asociate recomandate<\/h3>\n

                \u00cen diabet \u0219i endocrinologie<\/h3>\n
                  \n
                • Glicemie, HbA1c<\/li>\n
                • Autoanticorpi pancreatici (anti-GAD, IA-2, ZnT8)<\/li>\n<\/ul>\n

                  \u00cen boala celiac\u0103<\/h3>\n
                    \n
                  • Anti-transglutaminaz\u0103 tisular\u0103 (tTG IgA\/IgG)<\/li>\n
                  • Anti-endomisium (EMA)<\/li>\n
                  • IgA total<\/li>\n<\/ul>\n

                    \u00cen narcolepsie<\/h3>\n
                      \n
                    • Evaluare neurologic\u0103 specializat\u0103<\/li>\n
                    • Polisomnografie \/ test MSLT<\/li>\n<\/ul>\n

                      \u00cen boli autoimune<\/h3>\n
                        \n
                      • ANA, ENA panel<\/li>\n
                      • CRP, VSH<\/li>\n
                      • Alte markere specifice organului afectat<\/li>\n<\/ul>\n

                        Prob\u0103 recoltat\u0103 \/ condi\u021bii analiz\u0103<\/h3>\n

                        S\u00e2nge total EDTA<\/h3>\n
                          \n
                        • Nu necesit\u0103 preg\u0103tire special\u0103<\/li>\n<\/ul>\n

                          Documente obligatorii<\/h3>\n
                            \n
                          • Bilet de trimitere \/ recomandare medical\u0103<\/li>\n
                          • Date clinice relevante<\/li>\n
                          • Istoric familial de boli autoimune (dac\u0103 exist\u0103)<\/li>\n<\/ul>\n

                            Denumiri alternative<\/h3>\n
                              \n
                            • HLA class II genotyping (DR, DQ)<\/li>\n
                            • HLA-DR\/DQ molecular typing<\/li>\n
                            • HLA2 immunogenetic test<\/li>\n
                            • HLA-DR4 \/ DQ2 \/ DQ8 panel<\/li>\n
                            • HLA-DQB1*06:02 testing<\/li>\n
                            • Autoimmune HLA risk panel<\/li>\n
                            • Class II HLA susceptibility test<\/li>\n
                            • Immunogenetic HLA-DR\/DQ analysis<\/li>\n
                            • HLA disease association class II test<\/li>\n
                            • Biomnis HLA class II assay<\/li>\n<\/ul>\n

                              Particularit\u0103\u021bi ale testului<\/h3>\n

                              Aceast\u0103 analiz\u0103 de HLA clasa II<\/strong> identific\u0103 markeri genetici asocia\u021bi cu susceptibilitatea la boli autoimune \u0219i neuroimunologice. Prezen\u021ba unei alele HLA de risc reprezint\u0103, \u00een sine, un diagnostic de boal\u0103, ci indic\u0103 o predispozi\u021bie genetic\u0103 imunologic\u0103<\/strong>, ce trebuie corelat\u0103 cu datele clinice \u0219i cu alte investiga\u021bii de specialitate.<\/p>\n","protected":false},"excerpt":{"rendered":"

                              Analiz\u0103 genetic\u0103 de tip HLA clasa II<\/strong>, care determin\u0103 alelele din regiunile HLA-DR \u0219i HLA-DQ<\/strong>, inclusiv variantele clinice relevante DR4, DQ2, DQ8 \u0219i DQB1*06:02<\/strong>. Testul este utilizat \u00een evaluarea predispozi\u021biei la boli autoimune, diabet zaharat tip 1, boal\u0103 celiac\u0103 \u0219i narcolepsie.<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"inline_featured_image":false},"product_brand":[],"product_cat":[1209,3166,2876],"product_tag":[],"class_list":["post-26950","product","type-product","status-publish","product_cat-analize","product_cat-diagnostic-genetic","product_cat-serviciu-laborator","first","instock","sale","virtual","purchasable","product-type-simple"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t